journal article·2022-04-27

Cisplatin Nanoparticles Promote Intratumoral CD8+ T Cell Priming via Antigen Presentation and T Cell Receptor Crosstalk

Haochen Yao, Na Shen, Guofeng Ji, Juanjuan Huang, Jiali Sun, Guoqing Wang, Zhaohui Tang, Xuesi Chen

Nano Letters· Volume 22· Issue 8
Publisher page

Abstract

Nanomedicines are highly promising for cancer therapy due to their minimal side effects. However, little is known regarding their host immune response, which may limit their clinical efficacy and applications. Here, we find that cisplatin (CDDP)-loaded poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticles (CDDP-NPs) elicit a strong antitumor CD8+ T cell-mediated immune response in a tumor-bearing mouse model compared to free CDDP. Mechanistically, the sustained retention of CDDP-NPs results in persistent tumor MHC-I overexpression, which promotes the formation of MHC-I-antigen peptide complex (pMHC-I), enhances the interaction between pMHC-I and T cell receptor (TCR), and leads to the activation of TCR signaling pathway and CD8+ T cell-mediated immune response. Furthermore, CDDP-NPs upregulate the costimulatory OX40 on intratumoral CD8+ T cells, and synergize with the agonistic OX40 antibody (aOX40) to suppress tumor growth by 89.2%. Our study provides a basis for the efficacy advantage of CDDP-based nanomedicines and immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Zoonosis Research, Ministry of Education, College of Basic Medical Science, Jilin University, Changchun 130021, P.R. China

Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P.R. China

Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

School of Applied Chemistry and Engineering, University of Sciences and Technology of China, Hefei 230026, China

Funding

Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (80)

Show source-provided references
1. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
2. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
3. 10.1002/adfm.20210719510.1002/adfm.202107195 ↗
4. 10.1021/acsnano.1c0554710.1021/acsnano.1c05547 ↗
5. 10.1021/acs.nanolett.1c0081810.1021/acs.nanolett.1c00818 ↗
6. 10.1016/j.apsb.2020.09.00410.1016/j.apsb.2020.09.004 ↗
7. 10.1002/adma.20200808910.1002/adma.202008089 ↗
8. 10.1002/smll.20200482910.1002/smll.202004829 ↗
9. 10.1002/smll.20200286110.1002/smll.202002861 ↗
10. 10.1038/s41577-019-0269-610.1038/s41577-019-0269-6 ↗
11. 10.1002/anie.20200530910.1002/anie.202005309 ↗
12. 10.3389/fmicb.2019.0145810.3389/fmicb.2019.01458 ↗
13. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
14. 10.1021/acsnano.5b0367710.1021/acsnano.5b03677 ↗
15. 10.1007/s11095-010-0233-410.1007/s11095-010-0233-4 ↗
16. 10.1016/j.cllc.2012.11.00510.1016/j.cllc.2012.11.005 ↗
17. 10.1200/JCO.2005.04.93710.1200/JCO.2005.04.937 ↗
18. 10.1093/annonc/mdh09710.1093/annonc/mdh097 ↗
19. 10.1038/onc.2013.9410.1038/onc.2013.94 ↗
20. 10.1016/j.drup.2014.12.00210.1016/j.drup.2014.12.002 ↗
21. 10.1038/cdd.2013.6710.1038/cdd.2013.67 ↗
22. 10.1084/jem.2017068110.1084/jem.20170681 ↗
23. 10.1186/s13045-019-0742-510.1186/s13045-019-0742-5 ↗
24. 10.1093/neuonc/noz01510.1093/neuonc/noz015 ↗
25. 10.1038/s41568-019-0209-610.1038/s41568-019-0209-6 ↗
26. 10.1038/nrclinonc.2016.5710.1038/nrclinonc.2016.57 ↗
27. 10.1021/acs.accounts.9b0027310.1021/acs.accounts.9b00273 ↗
28. 10.1136/jitc-2020-00199610.1136/jitc-2020-001996 ↗
29. 10.1016/j.addr.2013.09.01410.1016/j.addr.2013.09.014 ↗
30. 10.1002/(SICI)1097-0215(19991210)83:6<848::AID-IJC29>3.0.CO;2-#10.1002/(SICI)1097-0215(19991210)83:6<848::AID-IJC29>3.0.CO;2-# ↗
31. 10.1002/cncr.2174210.1002/cncr.21742 ↗
32. 10.1016/S0090-8258(03)00472-410.1016/S0090-8258(03)00472-4 ↗
33. 10.3390/cancers1103043010.3390/cancers11030430 ↗
34. 10.1016/j.tiv.2019.05.00410.1016/j.tiv.2019.05.004 ↗
35. 10.1080/21691401.2019.160453510.1080/21691401.2019.1604535 ↗
36. 10.1016/j.ygyno.2014.01.04210.1016/j.ygyno.2014.01.042 ↗
37. Akamatsu K. · Anticancer Res. · 1993 · 13 · 2261
38. 10.3390/ijms1910318310.3390/ijms19103183 ↗
39. 10.1016/j.jconrel.2011.07.02610.1016/j.jconrel.2011.07.026 ↗
40. 10.1038/bjc.2011.610.1038/bjc.2011.6 ↗
41. 10.1111/cas.1207910.1111/cas.12079 ↗
42. 10.1038/sj.bjc.660277210.1038/sj.bjc.6602772 ↗
43. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
44. 10.1166/jbn.2016.215210.1166/jbn.2016.2152 ↗
45. 10.1158/1078-0432.CCR-17-108210.1158/1078-0432.CCR-17-1082 ↗
46. 10.1016/j.actbio.2015.02.00910.1016/j.actbio.2015.02.009 ↗
47. 10.1093/bioinformatics/btp69210.1093/bioinformatics/btp692 ↗
48. 10.1038/nrg248410.1038/nrg2484 ↗
49. 10.1016/j.jmoldx.2017.10.00110.1016/j.jmoldx.2017.10.001 ↗
50. 10.1038/s41598-017-11310-010.1038/s41598-017-11310-0 ↗
51. 10.1016/j.trecan.2019.02.00610.1016/j.trecan.2019.02.006 ↗
52. 10.1016/j.ejca.2015.08.02110.1016/j.ejca.2015.08.021 ↗
53. 10.1016/j.actbio.2021.08.01310.1016/j.actbio.2021.08.013 ↗
54. 10.1039/D1BM00112D10.1039/D1BM00112D ↗
55. 10.1016/j.ijpharm.2021.12057710.1016/j.ijpharm.2021.120577 ↗
56. 10.1093/nar/gkw109210.1093/nar/gkw1092 ↗
57. 10.1038/nri340310.1038/nri3403 ↗
58. 10.1016/j.molcel.2018.12.01810.1016/j.molcel.2018.12.018 ↗
59. 10.1073/pnas.210373011810.1073/pnas.2103730118 ↗
60. 10.1007/s00253-015-7104-110.1007/s00253-015-7104-1 ↗
61. 10.4049/jimmunol.171.11.572710.4049/jimmunol.171.11.5727 ↗
62. 10.1146/annurev.immunol.18.1.27510.1146/annurev.immunol.18.1.275 ↗
63. 10.1146/annurev-immunol-041015-05552310.1146/annurev-immunol-041015-055523 ↗
64. 10.3389/fimmu.2017.0079710.3389/fimmu.2017.00797 ↗
65. 10.1021/acsami.8b0934810.1021/acsami.8b09348 ↗
66. 10.1016/j.tibs.2017.11.00810.1016/j.tibs.2017.11.008 ↗
67. 10.1038/s41590-020-0732-310.1038/s41590-020-0732-3 ↗
68. 10.4049/jimmunol.180028410.4049/jimmunol.1800284 ↗
69. 10.1158/1078-0432.CCR-14-129810.1158/1078-0432.CCR-14-1298 ↗
70. 10.1089/cbr.2012.120310.1089/cbr.2012.1203 ↗
71. 10.1038/mt.2009.3210.1038/mt.2009.32 ↗
72. 10.1371/journal.pone.003254210.1371/journal.pone.0032542 ↗
73. 10.3892/ijo.2017.414210.3892/ijo.2017.4142 ↗
74. 10.1182/blood-2017-07-74102510.1182/blood-2017-07-741025 ↗
75. 10.1080/2162402X.2021.189226510.1080/2162402X.2021.1892265 ↗
76. 10.1136/jitc-2020-00096610.1136/jitc-2020-000966 ↗
77. 10.1158/0008-5472.CAN-12-417410.1158/0008-5472.CAN-12-4174 ↗
78. 10.1111/j.1600-065X.2011.01069.x10.1111/j.1600-065X.2011.01069.x ↗
79. 10.1073/pnas.180449311510.1073/pnas.1804493115 ↗
80. 10.1038/s41591-020-1131-x10.1038/s41591-020-1131-x ↗